Compare Stocks: MGX, MRNA, PEPG, and DTIL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$6.31 -0.3%	$7.28	$3.53 ▼ $9.62	$174.72M	1.27	243,111 shs	292,952 shs
MGX Metagenomi	$1.02 -7.7%	$1.18	$1.02 ▼ $3.95	$38.53M	0.69	139,558 shs	121,801 shs
MRNA Moderna	$190.01 +0.6%	$125.46	$22.28 ▼ $208.90	$75.43B	1.09	14.04 million shs	10.27 million shs
PEPG PepGen	$2.28 +3.2%	$2.74	$1.31 ▼ $7.80	$153.06M	2.01	848,313 shs	729,454 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	-0.32%	+1.45%	-15.30%	-22.86%	+15.99%
MGX Metagenomi	-7.69%	-11.30%	-12.07%	-19.05%	-57.32%
MRNA Moderna	+0.57%	-4.46%	+25.99%	+138.23%	+588.44%
PEPG PepGen	+3.17%	-11.97%	-28.30%	+29.55%	-51.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$6.31 -0.3%	$7.28	$3.53 ▼ $9.62	$174.72M	1.27	243,111 shs	292,952 shs
MGX Metagenomi	$1.02 -7.7%	$1.18	$1.02 ▼ $3.95	$38.53M	0.69	139,558 shs	121,801 shs
MRNA Moderna	$190.01 +0.6%	$125.46	$22.28 ▼ $208.90	$75.43B	1.09	14.04 million shs	10.27 million shs
PEPG PepGen	$2.28 +3.2%	$2.74	$1.31 ▼ $7.80	$153.06M	2.01	848,313 shs	729,454 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	-0.32%	+1.45%	-15.30%	-22.86%	+15.99%
MGX Metagenomi	-7.69%	-11.30%	-12.07%	-19.05%	-57.32%
MRNA Moderna	+0.57%	-4.46%	+25.99%	+138.23%	+588.44%
PEPG PepGen	+3.17%	-11.97%	-28.30%	+29.55%	-51.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DTIL Precision BioSciences	2.60	Moderate Buy	$32.25	411.09% Upside
MGX Metagenomi	2.75	Moderate Buy	$6.00	488.24% Upside
MRNA Moderna	2.08	Hold	$77.83	-59.04% Downside
PEPG PepGen	2.67	Moderate Buy	$11.40	400.00% Upside

Current Analyst Ratings Breakdown

Latest MGX, MRNA, PEPG, and DTIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$60.00 ➝ $80.00
9/25/2026	MRNA Moderna	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
9/23/2026	MRNA Moderna	Singular Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/22/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/22/2026	PEPG PepGen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/22/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/9/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/9/2026	MRNA Moderna	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/9/2026	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$81.00
9/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Sell

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DTIL Precision BioSciences	$45.06M	3.87	N/A	N/A	$4.03 per share	1.57
MGX Metagenomi	$13.56M	2.84	N/A	N/A	$4.22 per share	0.24
MRNA Moderna	$2.21B	34.33	N/A	N/A	$22.14 per share	8.58
PEPG PepGen	N/A	N/A	N/A	N/A	$2.14 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DTIL Precision BioSciences	-$45.72M	-$2.80	N/A	N/A	N/A	-96.73%	-72.52%	-32.25%	11/2/2026 (Estimated)
MGX Metagenomi	-$87.87M	-$2.49	N/A	N/A	N/A	-384.61%	-63.65%	-44.52%	11/10/2026 (Estimated)
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/5/2026 (Estimated)
PEPG PepGen	-$89.65M	-$1.31	N/A	N/A	N/A	N/A	-51.01%	-43.49%	11/11/2026 (Estimated)

Latest MGX, MRNA, PEPG, and DTIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	MGX Metagenomi	-$0.5531	-$0.73	-$0.1769	-$0.73	$3.01 million	($0.26) million
8/6/2026	Q2 2026	DTIL Precision BioSciences	-$0.8040	-$1.26	-$0.4560	-$1.26	$0.74 million	N/A
8/6/2026	Q2 2026	PEPG PepGen	-$0.2845	-$0.26	+$0.0245	-$0.26	N/A	N/A
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DTIL Precision BioSciences	0.50	12.82	12.82
MGX Metagenomi	N/A	4.50	4.50
MRNA Moderna	0.09	2.29	2.18
PEPG PepGen	N/A	13.36	13.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DTIL Precision BioSciences	37.99%
MGX Metagenomi	N/A
MRNA Moderna	75.33%
PEPG PepGen	58.01%

Insider Ownership

Company	Insider Ownership
DTIL Precision BioSciences	2.70%
MGX Metagenomi	12.50%
MRNA Moderna	10.80%
PEPG PepGen	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DTIL Precision BioSciences	67	27.60 million	26.86 million	No Data
MGX Metagenomi	113	37.78 million	33.06 million	N/A
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
PEPG PepGen	57	69.26 million	68.36 million	Not Optionable

MGX, MRNA, PEPG, and DTIL Headlines

Recent News About These Companies

PepGen, Inc. $PEPG Shares Bought by Squarepoint Ops LLC

September 18, 2026 | marketbeat.com

PepGen Inc. (PEPG) Interactive Stock Chart - Yahoo Finance

September 16, 2026 | finance.yahoo.com

PepGen, Inc. (NASDAQ:PEPG) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 10, 2026 | marketbeat.com

HC Wainwright Reiterates Buy Rating for PepGen (NASDAQ:PEPG)

September 9, 2026 | marketbeat.com

BlackRock Inc. Buys Shares of 1,304,262 PepGen, Inc. $PEPG

September 6, 2026 | marketbeat.com

DSMB approves dose escalation in PepGen’s FREEDOM2-DM1 study

August 7, 2026 | msn.com

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

August 6, 2026 | businesswire.com

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

August 6, 2026 | businesswire.com

PepGen Inc. (PEPG) Stock Price, News, Quote & History - Yahoo Finance

July 14, 2026 | finance.yahoo.com

PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

July 8, 2026 | stockhouse.com

PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

May 20, 2026 | zacks.com

10 Best NASDAQ Stocks Under $5 to Buy Right Now

May 18, 2026 | insidermonkey.com

Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?

May 18, 2026 | finance.yahoo.com

PepGen (PEPG) Upgraded to Buy: Here's What You Should Know

May 13, 2026 | zacks.com

PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 12, 2026 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

May 7, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

April 30, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

April 28, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and IDEAYA Biosciences (IDYA)

April 26, 2026 | theglobeandmail.com

Stifel Nicolaus Sticks to Its Buy Rating for PepGen Inc. (PEPG)

April 26, 2026 | theglobeandmail.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

April 21, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MGX, MRNA, PEPG, and DTIL Company Descriptions

Precision BioSciences NASDAQ:DTIL

$6.31 -0.02 (-0.32%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$6.30 -0.01 (-0.24%)

As of 10/2/2026 07:30 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Metagenomi NASDAQ:MGX

$1.02 -0.09 (-7.69%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.08 +0.06 (+6.27%)

As of 10/2/2026 08:00 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Moderna NASDAQ:MRNA

$190.01 +1.07 (+0.57%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$189.57 -0.44 (-0.23%)

As of 10/2/2026 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

PepGen NASDAQ:PEPG

$2.28 +0.07 (+3.17%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.26 -0.02 (-0.88%)

As of 10/2/2026 07:30 PM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MGX, MRNA, PEPG, and DTIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MGX, MRNA, PEPG, and DTIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MGX, MRNA, PEPG, and DTIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MGX, MRNA, PEPG, and DTIL Company Descriptions

Precision BioSciences NASDAQ:DTIL

Metagenomi NASDAQ:MGX

Moderna NASDAQ:MRNA

PepGen NASDAQ:PEPG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MGX, MRNA, PEPG, and DTIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MGX, MRNA, PEPG, and DTIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MGX, MRNA, PEPG, and DTIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MGX, MRNA, PEPG, and DTIL Company Descriptions

Precision BioSciences NASDAQ:DTIL

Metagenomi NASDAQ:MGX

Moderna NASDAQ:MRNA

PepGen NASDAQ:PEPG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools